A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Monoclonal antibodies (mAbs) are vital therapeutics targeting specific receptors.
• Existing literature often lacks concise summaries of mAb pharmacological profiles and clinical applications.
• A systematic classification of clinically used mAbs is needed for effective medical practice.

Purpose of the Study:

• To classify current monoclonal antibodies (mAbs) used in clinical practice based on the diseases they treat.
• To provide a brief synopsis of each mAb, including pharmacological profiles, mechanisms of action, uses, and side effects.
• To offer a useful resource for physicians in developing management protocols for mAb therapies.

Main Methods:

• Categorization of mAbs by disease systems (e.g., cardiovascular, musculoskeletal, autoimmune, oncology).
• Inclusion of specific examples of mAbs within each category, such as Abciximab, Denosumab, Adalimumab, and Trastuzumab.
• Discussion of emerging applications, including IL-6 antagonists like Tocilizumab and Siltuximab for COVID-19.

Main Results:

• The review classifies mAbs across various therapeutic areas, including cardiovascular, musculoskeletal, autoimmune disorders, and oncology.
• Pharmacological profiles, mechanisms of action, and clinical uses are summarized for key mAbs.
• Potential applications in treating COVID-19 with IL-6 antagonist mAbs are highlighted.

Conclusions:

• Monoclonal antibodies (mAbs) offer significant benefits for chronic and malignant diseases.
• This review provides a structured overview of mAb pharmacology, aiding physicians in treatment strategies.
• A comprehensive understanding of mAbs is crucial for optimizing patient care and management protocols.